Editas med stock.
Let’s look at Editas Medicine (NASDAQ:EDIT).I last mentioned Editas Medicine on Nov. 20, as it traded at around $10. Now up slightly, I expect it to push even higher on two key catalysts. One is ...
Shares of Editas Medicine ( EDIT 3.07%), a clinical-stage biotech company, fell by 15.5% in November, according to data from S&P Global Intelligence. The stock closed October at $12.55 a share ...Dec 1, 2023 · Stock Quote. Change Volume 52 Week High 52 Week Low Dec 2, 2023 5:42 PM EST. ... Editas Medicine, Inc. Phone: 617.401.0113 E-mail: [email protected] Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ...Successfully navigating the dynamic landscape of stock investing requires an understanding of factors like momentum to judge a stock’s price trend. In this article, we take an in-depth look at Editas Medicine Inc (EDIT) to unravel why momentum evaluation plays a crucial role in making savvy investment choices.Editas Medicine (NASDAQ:EDIT), a genome-editing company, has seen a significant 20% surge in its stock, marking its largest increase over two years. This …
Editas Medicine (EDIT, $10.13) RSI Indicator left the overbought zone on November 21, 2023. Tickeron - Stocks • 5 days ago. Investors Buy High Volume of Editas Medicine Call Options (NASDAQ:EDIT) Zolmax • 6 days ago. Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Find the latest Editas Medicine, Inc. (EDIT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Stock Quote. Change Volume 52 Week High 52 Week Low Dec 2, 2023 5:42 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. ... Editas Medicine, …
Founded. 2013. ISIN. US28106W1036. Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic …The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.View Georgia Giannoukos’ profile on LinkedIn, the world’s largest professional community. Georgia has 1 job listed on their profile. See the complete profile on LinkedIn and discover Georgia ...Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19.
Earnings for Editas Medicine are expected to decrease in the coming year, from ($2.40) to ($2.55) per share. Editas Medicine has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 28th, 2024 based off prior year's report dates. Read More.
Mar 10, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ...
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.Editas Medicine is forecast to grow earnings and revenue by 0.04% and 51.7% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be -133.7% in 3 years.Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Lastly, Caribou Biosciences, Prime Medicine, and Editas Medicine are all worth owning as a hedge against the highly uncertain nature of the field's long-term future.Shares of Editas Medicine ( EDIT -0.26%) were down as much as 21% at one point on Thursday. The stock closed at $12.25 on Wednesday and opened at only $9.90 on Thursday, falling to as low as $9.61 ...
That's why companies such as Editas Medicine ( EDIT 2.28%) and Intellia Therapeutics ( NTLA 1.74%) are down massively over the trailing 12-month period. However, Wall Street expects both to bounce ...11 ago 2021 ... The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise ...According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ...See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
Editas Medicine (EDIT) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.
Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ... Oct 5, 2023 · Take Editas Medicine (EDIT 2.28%) as an example. On June 9, it reported positive phase 1/2 data from one of its programs for sickle cell disease, then on June 14 it announced a stock offering ... Over the past year, shares of gene-editing companies Editas Medicine ( EDIT -0.23%) and CRISPR Therapeutics ( CRSP 6.42%) have shot up 129% and 212%, respectively. Their mouth-watering returns ...Nov 29, 2023 · Editas Medicine, Inc. - Hold. Zacks' proprietary data indicates that Editas Medicine, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the EDIT shares relative ... "Buying the dip" is another way to say purchasing a stock or an index after it's fallen in value. Learn how the strategy works and if it's right for you.One of the top gene-editing stocks on the market is Editas Medicine (EDIT 0.86%). The biotech has been in business for less than five years and has only traded publicly for a little over two years.Editas (EDIT) delivered earnings and revenue surprises of 14.06% and 5.50%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.
Name. Chg %. Market Cap. Molecular Templates Inc. 2.25%. $26.23M. EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. View real-time stock prices and …
With all that said, here are the most exciting genomic stocks that you won’t want to miss out on. NTLA Intellia Therapeutics $37.75 BEAM Beam Therapeutics $30.71 EDIT Editas Medicine $8.16.What happened. Shares of Editas Medicine (EDIT 3.31%) were up 12.7% this week, as of Thursday's close, according to data provided by S&P Global Market Intelligence.The biotech specializes in gene ...Sep 29, 2023 · Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy ... Editas Medicine Inc stock price live 10.42, this page displays NASDAQ EDIT stock exchange data. View the EDIT premarket stock price ahead of the market session or assess the after hours quote.Shares of Editas Medicine ( EDIT 11.39%) were skyrocketing 41.5% higher as of 11:57 a.m. EST on Monday. The company didn't announce any big news over the weekend or today, so why is the …Find the latest Editas Medicine, Inc. (EDIT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Open a brokerage account and deposit funds in it to purchase stock in a company, explains the Wall Street Journal. Companies such as Charles Schwab, E-Trade, and Ameritrade provide brokerage services.Editas Medicine is a clinical-stage company specializing in genome editing. Check out the reasons behind the recent surge in the EDIT stock.
Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19.11 ago 2021 ... The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise ...Stock Quote. Change Volume 52 Week High 52 Week Low Dec 2, 2023 5:42 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. ... Editas Medicine, …Instagram:https://instagram. natural gas marketwatchdarioush wineryalcohol stocksnasdaq khc Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote ...Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This … dividend yield sandp 500cronos group inc Nov 21, 2023 · The Editas Medicine stock prediction results are shown below and presented as a graph, table and text information. Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53. Today 200 Day Moving Average is the resistance level ... fidelity blue chip stock Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.Why Editas Medicine Stock Is Jumping Today. By Keith Speights – Nov 8, 2021 at 12:52PM ... Shares of Editas Medicine (EDIT 11.39%) were jumping 9.4% as of 12:27 p.m. EST on Monday. The gain came ...